search
Back to results

PROphylactic Mesh to Prevent Incisional Hernias at the Former Stoma Site: the PROMISS-trial (PROMISS)

Primary Purpose

Incisional Hernia

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Adhesix® monofilament polypropylene mesh (Bard Davol)
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Incisional Hernia

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosed with colorectal carcinoma
  • Bowel resection following stoma formation, intended to be temporary.
  • Elective surgery
  • ASA-score I-III
  • Signed informed consent

Exclusion Criteria:

  • Emergency operation
  • Peritonitis (i.e. bowel perforation)
  • Bowel obstruction
  • A life expectancy of less than 2 years (distant metastasis i.e. located in the liver, peritoneum, lung, cerebral or bone)
  • Earlier hernia repair with mesh placed in a 10cm proximity of the future stoma site.
  • Chronic use of antibiotics
  • Chronic use of immunosuppressive medication
  • ASA-score IV or above
  • Not able to sign informed consent
  • Patient being unable to speak Dutch
  • Patient allergic to one of the components of the mesh

Sites / Locations

  • Maastricht University Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Adhesix® monofilament polypropylene mesh (Bard Davol) group

Control group

Arm Description

The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.

The control group will not receive a mesh and the stoma will be created according local protocol.

Outcomes

Primary Outcome Measures

Occurrence of incisional hernia at the former stoma site.
Incidence of incisional hernia Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.

Secondary Outcome Measures

Occurrence of parastomal hernia
Incidence of parastomal hernia Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Occurence of prolapse
Incidence of prolapse Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Occurence of mesh infection
Incidence of mesh infection Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Occurence of wound infections
Incidence of wound infections Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Occurence of Seroma
Incidence of seroma Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Quality of life score
Quality of life postoperatively assessed through questionnaires. - EQ-5D-5L (0-25), lower is considered a better outcome
Quality of life score
Quality of life postoperatively assessed through questionnaires. - Carolina Comfort scale (0-40), lower is considered a better outcome.
Quality of life score
Quality of life postoperatively assessed through questionnaires. - EORTC QLQ-CR29 (0-228), lower is considered a better outcome.
Operation length
Time from start of the operation to finish (min), longer operation time can be an indication of a more complex procedure.
Time to stoma reversal
Time between creation of the stoma and its reversal, will be expressed in days. (minimum of 14 days to a maximum of 730 days). It will be measured from creation of stoma to reversal, which is 6 weeks on average, if the stoma is not reversed within 24 months the patient is excluded. For it will not be able to reach the primary endpoint. Delay of reversal of the stoma may indicate that patient condition or other patient related factors are not optimal.
Cost-effectiveness
Cost benefit analysis involving health cost and societal cost due to inability to participate in work. Lower health care cost are considered a better outcome, it is hypothesised that preventive treatment results in less cost by avoiding reoperations and readmission on the long term. Assessment will be performed using questionnaires; the iMCQ questionnaires for cost effectiveness analysis. The questions of the questionnaire will be analysed separately, for the questions range from yes/no questions to multiple choice or questions regarding number of days/ hours worked.
Cost-effectiveness
Cost benefit analysis involving health cost and societal cost due to inability to participate in work. Lower health care cost are considered a better outcome, it is hypothesised that preventive treatment results in less cost by avoiding reoperations and readmission on the long term. Assessment will be performed using questionnaires; the iPCQ questionnaires for cost effectiveness analysis. The questions of the questionnaire will be analysed separately, for the questions range from yes/no questions to multiple choice or questions regarding number of days/ hours worked.

Full Information

First Posted
November 16, 2018
Last Updated
November 20, 2018
Sponsor
Maastricht University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03750942
Brief Title
PROphylactic Mesh to Prevent Incisional Hernias at the Former Stoma Site: the PROMISS-trial
Acronym
PROMISS
Official Title
PROphylactic Mesh to Prevent Incisional Hernias at the Former Stoma Site: the PROMISS-trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Unknown status
Study Start Date
March 1, 2019 (Anticipated)
Primary Completion Date
March 1, 2023 (Anticipated)
Study Completion Date
March 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maastricht University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rationale: Approximately 7000 stomata are created in the Netherlands every year. The occurrence of a parastomal herniation is high, with a reported incidence of 4-48%. Also, the former stoma site is at increased risk for the development of an incisional hernia. A clinical incisional hernia rate of 30% is reported after stoma reversal. Herniation can cause pain, deformity and possibly incarceration, which results in a significant impact on the quality of life of the patient. The hypothesis of this study is that the use of a prophylactic mesh at the time of stoma formation leads to a lower incidence of incisional hernias after stoma reversal, an improved quality of life and therefore a possible cost reduction in healthcare. Objective: To evaluate the incidence of incisional hernias after stoma reversal after preventive mesh placement compared to no mesh placement. In addition, we aim to assess the effect of preventive mesh placement on the quality of life and the effect on healthcare cost reduction by avoiding re-intervention. Study design: A multicentre double blind randomized controlled trial with a total follow up of 24 months. Study population: Adults (18-99) undergoing bowel resection with the formation of a temporary stoma. Intervention: A preventive mesh will be placed using a sublay keyhole technique (pre-peritoneal, retromuscular) at stoma formation. The mesh will be left in situ after stoma reversal and the hole in the mesh will be closed, to prevent incisional herniation. Main study parameters/endpoints: Primary: Incidence of incisional hernias after stoma reversal Secondary: Quality of life, stoma related prolapse or parastomal herniation, cost effectiveness and mesh related complications. Nature and extent of the burden and the risks associated with participation, benefit and group relatedness: The standard surgical procedure for the treatment of parastomal hernias is used in a prophylactic fashion. As this is standard care in parastomal hernias the risks are minimal. The mesh that is used is CE approved. The burden of participation in this study is minimal for the patient all follow-up visits coincide with the regular visits for colorectal cancer. Hence, no extra outpatient department visits, and even no additional diagnostics nor other medical procedures that could potentially burden the patient, are required.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Incisional Hernia

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial
Masking
Participant
Allocation
Randomized
Enrollment
130 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Adhesix® monofilament polypropylene mesh (Bard Davol) group
Arm Type
Experimental
Arm Description
The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
The control group will not receive a mesh and the stoma will be created according local protocol.
Intervention Type
Device
Intervention Name(s)
Adhesix® monofilament polypropylene mesh (Bard Davol)
Intervention Description
The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
Primary Outcome Measure Information:
Title
Occurrence of incisional hernia at the former stoma site.
Description
Incidence of incisional hernia Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Occurrence of parastomal hernia
Description
Incidence of parastomal hernia Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Time Frame
24 months
Title
Occurence of prolapse
Description
Incidence of prolapse Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Time Frame
24 months
Title
Occurence of mesh infection
Description
Incidence of mesh infection Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Time Frame
24 months
Title
Occurence of wound infections
Description
Incidence of wound infections Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Time Frame
24 months
Title
Occurence of Seroma
Description
Incidence of seroma Expressed in % ranging from 0-100%, a lower percentage is considered a better outcome.
Time Frame
24 months
Title
Quality of life score
Description
Quality of life postoperatively assessed through questionnaires. - EQ-5D-5L (0-25), lower is considered a better outcome
Time Frame
24 months
Title
Quality of life score
Description
Quality of life postoperatively assessed through questionnaires. - Carolina Comfort scale (0-40), lower is considered a better outcome.
Time Frame
24 months
Title
Quality of life score
Description
Quality of life postoperatively assessed through questionnaires. - EORTC QLQ-CR29 (0-228), lower is considered a better outcome.
Time Frame
24 months
Title
Operation length
Description
Time from start of the operation to finish (min), longer operation time can be an indication of a more complex procedure.
Time Frame
during operation
Title
Time to stoma reversal
Description
Time between creation of the stoma and its reversal, will be expressed in days. (minimum of 14 days to a maximum of 730 days). It will be measured from creation of stoma to reversal, which is 6 weeks on average, if the stoma is not reversed within 24 months the patient is excluded. For it will not be able to reach the primary endpoint. Delay of reversal of the stoma may indicate that patient condition or other patient related factors are not optimal.
Time Frame
time from stoma creation to reversal
Title
Cost-effectiveness
Description
Cost benefit analysis involving health cost and societal cost due to inability to participate in work. Lower health care cost are considered a better outcome, it is hypothesised that preventive treatment results in less cost by avoiding reoperations and readmission on the long term. Assessment will be performed using questionnaires; the iMCQ questionnaires for cost effectiveness analysis. The questions of the questionnaire will be analysed separately, for the questions range from yes/no questions to multiple choice or questions regarding number of days/ hours worked.
Time Frame
24 months
Title
Cost-effectiveness
Description
Cost benefit analysis involving health cost and societal cost due to inability to participate in work. Lower health care cost are considered a better outcome, it is hypothesised that preventive treatment results in less cost by avoiding reoperations and readmission on the long term. Assessment will be performed using questionnaires; the iPCQ questionnaires for cost effectiveness analysis. The questions of the questionnaire will be analysed separately, for the questions range from yes/no questions to multiple choice or questions regarding number of days/ hours worked.
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Diagnosed with colorectal carcinoma Bowel resection following stoma formation, intended to be temporary. Elective surgery ASA-score I-III Signed informed consent Exclusion Criteria: Emergency operation Peritonitis (i.e. bowel perforation) Bowel obstruction A life expectancy of less than 2 years (distant metastasis i.e. located in the liver, peritoneum, lung, cerebral or bone) Earlier hernia repair with mesh placed in a 10cm proximity of the future stoma site. Chronic use of antibiotics Chronic use of immunosuppressive medication ASA-score IV or above Not able to sign informed consent Patient being unable to speak Dutch Patient allergic to one of the components of the mesh
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicole D Bouvy, MD, PhD
Phone
+3143-3875492
Email
n.bouvy@mumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Sebastiaan Steensel, MD
Phone
+3143-3872354
Email
s.vansteensel@maastrichtuniversity.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicole D Bouvy, MD, PhD
Organizational Affiliation
Maastricht University Medical Centre, department of Surgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maastricht University Medical Centre
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 HX
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Bouvy, MD, PhD
Phone
043-3875492
Email
n.bouvy@mumc.nl

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

PROphylactic Mesh to Prevent Incisional Hernias at the Former Stoma Site: the PROMISS-trial

We'll reach out to this number within 24 hrs